Naveen Mittal
Pediatric Gastroenterology · Dallas, TXNPI 1114989977
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 31.6% of the total. 2025 is the largest year on record at $61,748, 2.6 times the $23,522 reported in 2019. Among pediatric gastroenterology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $792.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$58K
- Fresenius Kabi USA, LLC$50K
- Albireo Pharma, Inc.$30K
- Mirum Pharmaceuticals, Inc.$19K
- AstraZeneca$14K
- Travere Therapeutics, Inc.$10K
- plus $2K from 13 others
Across 71 payments — averaging $2754.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirum Pharmaceuticals, Inc.$105K
- Albireo Pharma, Inc.$36K
- AbbVie$28K
- Gilead$27K
What the payments were for
- Consulting fees$85,29947%
- Speaking & faculty fees$70,43039%
- Travel & lodging$17,2769%
- Food & beverage$9,2725%
- Gifts$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 44 | $57,648 |
| Fresenius Kabi USA, LLC | 81 | $50,136 |
| Albireo Pharma, Inc. | 18 | $30,217 |
| Mirum Pharmaceuticals, Inc. | 27 | $18,702 |
| AstraZeneca(2 entities) | 13 | $14,018 |
| Travere Therapeutics, Inc. | 23 | $9,885 |
| AbbVie | 4 | $393 |
| Novo Nordisk | 2 | $240 |
| Medtronic | 3 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $165 |
| Intercept Pharmaceuticals, Inc. | 1 | $124 |
| Vertex | 1 | $109 |
| Pfizer | 1 | $92 |
| Alcresta Therapeutics, Inc. | 4 | $91 |
| Blueprint Medicines Corporation | 1 | $87 |
| Veloxis Pharmaceuticals, Inc. | 1 | $51 |
| Regeneron Healthcare Solutions, Inc. | 1 | $42 |
| Nestle Healthcare Nutrition Inc. | 1 | $31 |
| Taiho Oncology, Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bylvay$86,979
- Smoflipid$32,245
- Livmarli$15,986
- PH-Omegaven$12,851
- (815) Thiola$9,274
- (820) Cholbam$315
- EndoFlip$148
- Strensiq$125
- Wegovy$125
- Creon$118
- Mavyret$117
- Ozempic$115
- SYMDEKO$109
- IQIRVO$103
How this compares
$182,281 in reported general payments places this provider in the 95th percentile of 159 pediatric gastroenterology providers in Texas.
Other pediatric gastroenterology in Dallas
- Amal AqulDallas$99K
- Charina RamirezDallas$60K
- Meghana SatheDallas$30K
- David TroendleDallas$14K
- Nandini ChannabasappaDallas$12K
- Rinarani SanghaviDallas$6K
- Bradley BarthDallas$6K
- Ricardo Medina-CentenoDallas$5K
- Megha MehtaDallas$4K
- Bhaskar GurramDallas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.